Latest news with #Vertex
Channel Post MEA
2 days ago
- Business
- Channel Post MEA
Infosys Launches Over 200 Enterprise AI Agents
Infosys has announced the launch of over 200 enterprise AI agents powered by Infosys Topaz AI offerings and Google Cloud's Vertex AI Platform. The AI agents are designed to drive tangible outcomes for enterprises by transforming complex workflows and managing intricate, multi-agent business operations efficiently at scale. These enterprise AI agents cater to multiple sectors, including healthcare, finance, retail, telecom, manufacturing, and agriculture. Leveraging advanced machine learning and cognitive architecture, the agents are equipped with powerful capabilities such as data extraction to transform raw inputs into actionable insights and multimodal functionality to handle diverse data types effectively. They ensure secure communication through encrypted channels and uphold robust data privacy measures to protect sensitive information. Additionally, the enterprise AI agents feature autonomous decision-making, which allows them to independently analyze scenarios and execute complex tasks, driving enhanced operational efficiency. For example: In the area of predictive network capacity planning, a monitoring agent continuously tracks real-time network capacity and alerts for any immediate concerns. This proactive monitoring helps prevent potential network issues, enhancing reliability and efficiency. It leads to reduced downtime, improved user experience, and optimized resource utilization. In the accounts payable and receivable processes, a corporate finance agent ensures accurate financial reporting and cash flow management, thus reducing the risk of late payments or missed collections, enhancing overall financial efficiency and reliability. In the manufacturing domain, a forecasting agent uses real-time data to predict demand for vehicle parts, thus optimizing inventory and managing the supply chain. This approach adjusts production, evaluates inventory, and auto-orders shortfall parts, boosting operational effectiveness and reliability. Balakrishna D. R. (Bali), Executive Vice President, Global Services Head, AI and Industry Verticals, Infosys, said, 'The development of more than 200 enterprise AI agents marks a milestone in our continued efforts to innovate and lead in the enterprise AI space. With Infosys Topaz AI offerings and Google Cloud's advanced AI frameworks, we are enhancing Human+AI collaboration and unlocking new levels of efficiency and precision across industries. This initiative not only demonstrates our capabilities but also reinforces our commitment to helping businesses navigate their next.' 'Enterprise AI agents have the power to improve operations by driving efficiency, reducing costs, and enhancing decision-making processes,' said Victor Morales, Vice President of GSI and Consulting Partnerships, Google Cloud. 'Infosys' enterprise AI agents, built on Google Cloud's Vertex AI platform, can enable businesses to improve complex workflows and support multi-agent operations at scale.' The AI agents mark a significant milestone as a direct outcome of the Google Cloud Center of Excellence, powered by Infosys Topaz. The initiative leverages the advanced AI capabilities of Infosys Topaz and the generative AI technology of Google Cloud to deliver innovative enterprise AI solutions. 0 0
Globe and Mail
3 days ago
- Business
- Globe and Mail
BMO Capital Markets Reiterates ‘Buy' Rating on Eli Lilly Stock (LLY)
BMO Capital Markets (BMO) has reiterated its Buy-equivalent outperform rating on Eli Lilly (LLY) stock with a $900 price target on the shares. Confident Investing Starts Here: Analyst Evan Seigerman reaffirmed his strong outlook for LLY stock after the U.S. pharmaceutical giant announced its plans to acquire privately held SiteOne Therapeutics for $1 billion in a deal that will give Eli Lilly greater access to non-opioid pain medication. Seigerman says the purchase of SiteOne is a smart strategic move on the part of Eli Lilly that will bolster its portfolio of pain management medications, positioning it to better compete with companies such as Vertex (VRTX). SiteOne's leading pain drug is currently in a Phase 2 clinical trial. Committed to Pain Management 'Lilly is expanding its presence in pain and looking to compete with the likes of Vertex with this announced deal to acquire privately held SiteOne therapeutics for as much as $1B,' wrote Seigerman in a note to clients about Eli Lilly. BMO Capital Markets adds that the deal to buy SiteOne underscores Eli Lilly's commitment to the pain treatment market, where it has long had a presence. By integrating SiteOne's products into its own line-up, Eli Lilly should gain a competitive edge in the pain management space, said Seigerman. Is LLY Stock a Buy? The stock of Eli Lilly has a consensus Strong Buy recommendation among 18 Wall Street analysts. That rating is based on 16 Buy, one Hold, and one Sell recommendations issued in the last 12 months. The average LLY price target of $1,003.14 implies 34.82% upside from current levels. Disclaimer & Disclosure Report an Issue
Boston Globe
4 days ago
- Business
- Boston Globe
John Donohue steps down from CEO role at Arbella
Today, Donohue estimates Arbella collects about $1.2 billion in premiums each year, across four New England states, compared with $200 million at its outset. Advertisement While Donohue chaired the Arbella board since the company's inception, he didn't step in as chief executive until 2001, taking over for Richard Brewer . Donohue says he's looking forward to focusing more on Arbella's foundation, which doles out $2.2 million a year to hundreds of organizations, and that he will be its chief executive, a part-time job. Donohue has confidence in Brady's leadership abilities after 12 years of working with him. Brady, who also has a decade of experience at Liberty Mutual, knows how the 1,100-person company is run and has built solid relationships with many of its outside agents. Arbella remains committed to its 'independent agent' model, despite the rise of direct, online insurance sales, in part because of the guidance the agents provide to customers. Advertisement For Donohue, the final months at Arbella have been a bittersweet time, without Bellotti, his mentor and friend. 'I would sit down and bounce ideas off him and talk strategy ... up until the end,' Donohue said. 'We got to work together for 44 years. ... We always said it was longer than most marriages.' Final piece for Fan Pier The Fallon Co. celebrated a topping-off ceremony for its 122-condo tower at Fan Pier on May 23. Photo courtesy of The Fallon Co. It all started with a helium balloon ride. Al Vaz , then the head of real estate at Vertex Pharmaceuticals , was visiting Fan Pier nearly two decades ago. At the time, the 21-acre site was not much more than a windswept stretch of parking lots. Developer Joe Fallon 's namesake firm used the balloon to show off its potential. Vaz, as Fallon recalls today, called Vertex's then-chief executive Josh Boger right away. Boger then visited the site and was smitten, too; he eventually inked a deal to bring the biotech and more than 1,000 of its employees to Fan Pier from Cambridge. The move in turn kicked off Fan Pier's redevelopment, jump-starting the Seaport's building boom. Last week, Fallon and colleagues joined the Iron Workers Local 7 and general contractor Turner Construction to help put the final piece of Fan Pier into place in a topping-off ceremony. They raised a steel girder to the top of the 14-story frame of what will be a 122-unit luxury condo project, dubbed 'One Harbor Shore.' ( Bank OZK provided financing last year, and MassMutual is Fallon's equity partner.) Advertisement When it opens in mid-2026, the building, designed by CBT Architects , will be among the first major privately developed structures in the city to rely almost entirely on electric heat. (Gas fired boilers will kick in when temps get close to zero degrees Fahrenheit.) Fan Pier now includes the two Vertex towers, the One Marina Park Drive tower where Fallon's company is located, as well as office buildings for MassMutual and Goodwin . Plus: more than 200 luxury waterfront condos at 22 and 50 Liberty. The Collaborative Companies will start marketing the units at One Harbor Shore in the coming weeks. 'We're proud of what we have, and we're proud of what it did for the city,' Fallon said. 'This site really became the catalyst for the whole Seaport.' Banking on Boston's Pride The scene at the Boston Pride for the People parade and festival last year. Craig F. Walker/Globe Staff Pride parades from Not in Boston. One of the leaders hosting Boston's Pride parade and festival to celebrate the region's LGBTQ+ community said fund-raising is now on a similar pace to last year, when around $700,000 was raised. So far, the total is in the $600,000 range, with more expected as the June 14 date approaches. Gary Daffin , of Boston Pride for the People's executive committee, says nearly half of that amount last year came from corporate sponsorships, and nearly half came from registration fees. (The group is affiliated with the Advertisement Daffin expects a similar budget this time around. So far, big sponsors are back — a list that includes Delta Air Lines , MFS Investment Management , the Boston Foundation , Beth Israel Lahey Health , Eastern Bank , MassMutual , Rockland Trust , Dana-Farber Cancer Institute , Eversource , and National Grid . Big-ticket corporate sponsorships range from $10,000 to $50,000. He said a few previous sponsors have not yet committed, but they're not among the big contributors. Daffin said the organizers had been concerned that fund-raising could take a hit because of economic uncertainties and the anti-DEI rhetoric in Washington. 'There was a fear that people were not going to reply to our requests,' Daffin said. 'But almost everyone who was there last year is back. ... It's a relief, though we still need a little bit more money. We're not there yet.' US Chamber to Boston: Be more welcoming Greater Boston Chamber of Commerce chief executive Jim Rooney chatted with US Chamber chief executive Suzanne Clark at the Boston Chamber's annual meeting. Photo courtesy of the Greater Boston Chamber US Chamber of Commerce chief executive Suzanne Clark has some advice for Boston's business leaders: Don't be afraid to be more welcoming to outsiders, particularly those with a different viewpoint. The suggestion emerged after Clark's speech at the Greater Boston Chamber of Commerce 's annual meeting, which drew around 1,400 people to the Omni Hotel in the Seaport last week. Greater Boston Chamber chief executive Jim Rooney asked Clark to talk about how Boston and Massachusetts are viewed around the country in terms of competitiveness and business friendliness. Clark, whose group is more conservative than the Boston chamber, had many good things to say about Boston, praising everything from Fenway Park to the local innovation ecosystem. But her answer to Rooney's question prompted one of the evening's few unscripted moments. 'I would say that it's almost all positive,' Clark said. '[But] there is something going on right now where you have to decide what inclusive means to you, you know? Does diversity include conservative thought? Because there are a lot of people in this country who aren't sure, right? There's a lot of conversation about: Would I be welcome in Boston? Would I be welcome at some of the elite institutions? Would my viewpoint be welcome?' Advertisement On taxes and deregulation, the US Chamber is in strong alignment with President Trump. But they differ on tariffs, and the chamber recently sent a request to the Trump administration asking for exemptions for small businesses. Mostly, in her chamber speech, Clark made the case for stoking economic growth, saying that while it can't solve all of the nation's problems, it's tough to solve many of them without that growth. The chamber also honored its latest set of 'Distinguished Bostonians' for contributing to Boston's economic and social fabric. Honorees included Jane Steinmetz of Ernst & Young , Michael Curry of the Massachusetts League of Community Health Centers , and Anne Klibanski of Mass General Brigham . The chamber's previous board chairs, along with current chair Corey Thomas , feted Rooney with a video for his 10 years as chief executive. And Governor Maura Healey bounded up on stage to provide some encouragement to the business leaders while also making the case why she should be elected again in 2026. 'In a time of crisis, use it as an opportunity,' Healey said. 'We proved that 250 years ago when shots rang out by a bridge in Concord and a green in Lexington. That's Massachusetts. That's in our DNA. ... We're going to get through this and we're going to be stronger for it.' Advertisement Jon Chesto can be reached at
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
Infosys unveils over 200 AI agents under Topaz in Google Cloud tie-up
Infosys has launched more than 200 enterprise AI agents as part of its Infosys Topaz™ AI offerings in collaboration with Google Cloud's Vertex AI platform. The initiative marks a significant milestone in the company's ambition to transform enterprise operations through next-generation artificial intelligence. The AI agents, developed using Google Cloud's agentic AI framework, are designed to manage complex workflows and support multi-agent operations at scale. These intelligent agents cater to sectors such as healthcare, finance, manufacturing, telecom, retail, and agriculture. Enhancing efficiency through autonomous AI The agents are equipped with capabilities such as autonomous decision-making, real-time monitoring, data extraction, and multimodal processing. They ensure secure data handling and communication, and can independently analyse business scenarios and execute tasks. A step forward in human-AI collaboration Balakrishna DR, Executive Vice President and Global Services Head at Infosys, said, 'The development of more than 200 enterprise AI agents marks a milestone in our continued efforts to innovate and lead in the enterprise AI space. We are enhancing Human+AI collaboration and unlocking new levels of efficiency and precision.' Victor Morales, Vice President of GSI and Consulting Partnerships at Google Cloud, added, 'Infosys' enterprise AI agents, built on Google Cloud's Vertex AI platform, can improve complex workflows and support multi-agent operations at scale.' Built from Google Cloud Centre of Excellence The new suite of AI agents is a direct outcome of the Google Cloud Center of Excellence, powered by Infosys Topaz™. This initiative combines the strengths of Infosys' AI innovation with Google Cloud's generative AI technologies to deliver scalable, intelligent enterprise solutions. With this launch, Infosys reaffirms its commitment to driving digital transformation through AI-first strategies, helping global businesses 'navigate their next'.
Yahoo
23-05-2025
- Business
- Yahoo
High Growth Tech Stocks In The US Market To Watch
As the U.S. market experiences a slight dip following a strong rally in the S&P 500, investors are closely monitoring economic indicators and broader market sentiment that impact small-cap companies. In this environment, identifying high-growth tech stocks involves looking for companies with robust earnings potential and resilience to economic fluctuations, making them noteworthy candidates in today's dynamic landscape. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 26.38% 39.09% ★★★★★★ Ardelyx 20.57% 59.97% ★★★★★★ Legend Biotech 26.73% 58.77% ★★★★★★ Travere Therapeutics 25.82% 65.45% ★★★★★★ TG Therapeutics 26.46% 38.75% ★★★★★★ Alnylam Pharmaceuticals 23.65% 61.11% ★★★★★★ AVITA Medical 27.28% 60.66% ★★★★★★ Alkami Technology 20.54% 76.67% ★★★★★★ Ascendis Pharma 35.16% 60.26% ★★★★★★ Lumentum Holdings 21.59% 110.32% ★★★★★★ Click here to see the full list of 234 stocks from our US High Growth Tech and AI Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Growth Rating: ★★★★★☆ Overview: Vertex, Inc. offers enterprise tax technology solutions for retail, wholesale, and manufacturing sectors globally and has a market capitalization of approximately $6.05 billion. Operations: Vertex, Inc. generates revenue primarily from its software and programming segment, which accounts for $687.06 million. Vertex's recent strategic partnership with Majesco, integrating its tax solutions into the ClaimVantage platform, underscores its commitment to enhancing operational efficiency and accuracy in tax calculations for disability claims. This move not only boosts Vertex's service offerings but also expands its market reach in Canada with plans to extend to U.S. customers later this year. Financially, Vertex reported a significant increase in Q1 2025 revenue, rising to $177.06 million from $156.78 million the previous year, alongside a substantial growth in net income from $2.68 million to $11.13 million. These figures reflect Vertex's robust financial health and innovative edge in developing solutions that address complex regulatory challenges, positioning it well for future expansion and profitability as indicated by their optimistic revenue forecasts of up to $768 million for 2025. Navigate through the intricacies of Vertex with our comprehensive health report here. Assess Vertex's past performance with our detailed historical performance reports. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in RNA-targeted therapeutics and gene therapies for rare diseases, with a market cap of $3.58 billion. Operations: Sarepta Therapeutics focuses on discovering, developing, manufacturing, and delivering RNA-targeted therapeutics and gene therapies for rare diseases, generating $2.23 billion in revenue. Sarepta Therapeutics, a trailblazer in gene therapies for Duchenne muscular dystrophy, recently showcased promising results from its ENDEAVOR study. Treatment with ELEVIDYS demonstrated significant dystrophin protein expression, a crucial factor for disease management. Despite facing challenges such as elevated liver enzymes in some patients, Sarepta's rigorous monitoring and adaptive treatment strategies underscore its commitment to safety and efficacy. The company's strategic focus on innovative gene therapies not only enhances its portfolio but also positions it well within the high-growth biotech sector, despite a recent downward adjustment in revenue projections to $2.3 billion for 2025. Unlock comprehensive insights into our analysis of Sarepta Therapeutics stock in this health report. Gain insights into Sarepta Therapeutics' historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Ciena Corporation is a network technology company that offers hardware, software, and services to network operators across multiple regions including the Americas, Europe, the Middle East, Africa, the Asia Pacific, Japan, and India with a market capitalization of approximately $11.55 billion. Operations: Ciena generates revenue primarily from its Networking Platforms segment, which accounts for $3.06 billion, followed by Global Services at $540.45 million. The Platform Software and Services and Blue Planet Automation Software and Services segments contribute $363.38 million and $89.71 million, respectively. Despite a challenging year with earnings growth down by 64.7%, Ciena's commitment to innovation remains robust, as evidenced by its significant R&D investment and recent technological advancements. The company has successfully trialed its WaveLogic 6 Extreme technology over an impressive distance of 1,590 kilometers, showcasing potential for future high-bandwidth applications. This aligns with a revenue growth forecast of 9.4% annually, outpacing the US market average of 8.5%. With earnings expected to surge by 51% annually, Ciena is strategically positioned to capitalize on increasing demand for advanced network solutions, despite current profit margins standing at a modest 2%. Click here to discover the nuances of Ciena with our detailed analytical health report. Review our historical performance report to gain insights into Ciena's's past performance. Reveal the 234 hidden gems among our US High Growth Tech and AI Stocks screener with a single click here. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:VERX NasdaqGS:SRPT and NYSE:CIEN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
